Clearmind Medicine达成重大里程碑,完成FDA监管I/II期试验A部分治疗

美股速递
Jun 22

Clearmind Medicine, Inc. 在药物研发道路上取得了一项关键进展,成功完成了其在美国食品药品监督管理局监管下的I/II期临床试验中的A部分治疗阶段。这标志着该公司在探索其候选药物的安全性与有效性方面迈出了坚实的一步,为其后续的临床开发计划奠定了重要基础。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10